If this is the case, treatment with Bromodomain and Extra Terminal inhibitors such as I-BET151 and JQ-1 potently suppress NF-κB signaling in melanoma, providing a rationale the use of these inhibitors in combination with MAPK inhibitors [54]. The gene discussed is NFKB1; the disease is melanoma.